# Preparing for the long haul



Media & Entertainment > Analyst Meet Update > August 24, 2024

We attended Saregama's analyst meet (as part of RPSG investor day) where the management reiterated its revenue guidance (excluding Carvaan) of 25-26% over the next 3 years. The core music licensing should log 23% CAGR with improvement in margins on account of leadership and scale benefits. This will be supported by steady catalog growth and investment of Rs1bn in new content, which also ensures that the company remains relevant over the long term. In the video segment, Saregama is at a relatively nascent stage and should see growth of 25-30% over the next 3 years with margin improvement given a bigger library and scale. PBT growth should be slower in the next 6 quarters as the company ramps up content acquisition and integrates Pocket Aces, after which PBT growth should outpace revenue growth. We maintain our estimates and retain BUY with an unchanged DCF-based TP of Rs580/share.

Saregama India: Financial Snapshot (Consolidated)							
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E		
Revenue	7,366	8,030	10,918	13,105	15,566		
EBITDA	2,210	2,466	3,145	4,084	5,137		
Adj. PAT	1,853	1,976	2,231	2,859	3,632		
Adj. EPS (Rs)	9.6	10.2	11.6	14.8	18.8		
EBITDA margin (%)	30.0	30.7	28.8	31.2	33.0		
EBITDA growth (%)	18.1	11.6	27.6	29.8	25.8		
Adj. EPS growth (%)	21.5	6.6	12.9	28.1	27.0		
RoE (%)	13.6	14.1	14.5	16.6	18.5		
RoIC (%)	31.8	19.9	17.4	19.0	21.3		
P/E (x)	54.7	51.3	45.4	35.4	27.9		
EV/EBITDA (x)	42.0	38.2	30.2	23.3	18.4		
P/B (x)	7.5	6.9	6.3	5.6	4.8		
FCFF yield (%)	(0.1)	0.0	(0.4)	0.1	1.3		

Source: Company, Emkay Research

#### Music licensing and artist management: Investing for the long term

Music licensing remains the backbone of the company. The management is ramping up on new music acquisition to future proof the company for the long term. This will entail investment of Rs10bn over the next 3 years, with payback period of 5 years being maintained. This investment will likely be split equally between Hindi and Regional music with margin profile being slightly better on the regional side. The old catalogue continues to see steady growth of 10-12% with 75-80% margin. Being a pan-India player allows Saregama to monetize its content in a better way. The competitive intensity is not high, with most languages seeing only few players competing for the new music being sold. The company has invested heavily in marketing and analytics which sets it apart from the competitors. It works with all major movie studios. The artist management segment is a byproduct of new music and does not require any upfront investment, while also improving music margins.

## Video: Strong growth from a low base

Saregama has the entire gamut of video offerings - from short clips to web series and movies. In the movies segment, it will continue to only operate in the regional space where the risk is lower. The company ensures that 70% of expenses are recovered before the release of the movie with all charges written off at the time of release. Most of Saregama's competitors also have their own movie production houses. The movie business has high IRR but low margins. For web series as well, the risk is minimized by securing deals with platforms prior to start of production. Over the next 12-18 months the company is looking at an 8-10% margin for this segment.

#### Other segments: Focus on margins for Carvaan; events in test mode

In the Carvaan segment, the focus is now clearly on generating higher margins as opposed to revenue growth. With the elder generation also now becoming accustomed to streaming, the life cycle of the product has become limited. Live concerts are a low margin and high-IRR segment. It allows the company to develop deeper relationships with the artists. Saregama has already hosted various concerts with Diljit Dosanjh.

### **TARGET PRICE (Rs): 580**

Target Price – 12M	Jun-25
Change in TP (%)	-
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	10.4
CMP (23-Aug-24) (Rs)	525.5


Stock Data	Ticker
52-week High (Rs)	581
52-week Low (Rs)	310
Shares outstanding (mn)	192.8
Market-cap (Rs bn)	101
Market-cap (USD mn)	1,208
Net-debt, FY25E (Rs mn)	-6,410
ADTV-3M (mn shares)	1
ADTV-3M (Rs mn)	377.5
ADTV-3M (USD mn)	4.5
Free float (%)	40.7
Nifty-50	24,823
INR/USD	83.9
Shareholding, Jun-24	
Promoters (%)	59.2
FPIs/MFs (%)	17.2/3.2

Price Performance						
(%)	1M	3M	12M			
Absolute	(1.4)	12.7	32.9			
Rel. to Nifty	(2.8)	4.3	4.1			




Pulkit Chawla pulkit.chawla@emkavalobal.com +91 22 6624 2458

Exhibit 1: Revenue growth to remain healthy




Source: Company, Emkay Research

Exhibit 2: Margins to be impacted in FY25 on account of content investment and acquisition




Source: Company, Emkay Research

Exhibit 3: Investment in new music bearing fruit



Source: Company, Emkay Research

Exhibit 4: Ramping up new content acquisition



Source: Company

Exhibit 5: Saregama's FY25 Music Release Calendar

Film Title	Language	Number of Songs
Bad Newz	Hindi	7
Sky Force	Hindi	4
Stree 2	Hindi	4
Jigra	Hindi	6
Sarzameen	Hindi	4
Kanguva	Tamil	5
Train	Tamil	4
Kingston	Tamil	4
Valli Mayil	Tamil	4
Jalsa	Tamil	5
Game Changer	Telugu	5
G.O.A.T	Telugu	5
Kalki 2898 AD	Telugu	7
Krishnamma	Telugu	5
Dilruba	Telugu	5
Bazooka	Malayalam	2
Nunakuzhi	Malayalam	4
Pavi Caretaker	Malayalam	5
Nandanna Sambavam	Malayalam	3
Guruvayoor	Malayalam	4
Martin	Kannada	4
Max	Kannada	4
Devil	Kannada	5
Kichcha 47	Kannada	4
Shivanna 130	Kannada	4

Source: Company, Emkay Research

## Saregama India: Consolidated Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Revenue	7,366	8,030	10,918	13,105	15,566
Revenue growth (%)	26.9	9.0	36.0	20.0	18.8
EBITDA	2,210	2,466	3,145	4,084	5,137
EBITDA growth (%)	18.1	11.6	27.6	29.8	25.8
Depreciation & Amortization	208	362	539	644	662
EBIT	2,002	2,104	2,606	3,440	4,475
EBIT growth (%)	15.0	5.1	23.9	32.0	30.1
Other operating income	0	0	0	0	0
Other income	536	637	408	413	412
Financial expense	57	32	33	33	33
PBT	2,481	2,708	2,982	3,821	4,854
Extraordinary items	0	0	0	0	0
Taxes	630	732	750	962	1,222
Minority interest	(3)	0	0	0	0
Income from JV/Associates	0	0	0	0	0
Reported PAT	1,853	1,976	2,231	2,859	3,632
PAT growth (%)	21.5	6.6	12.9	28.1	27.0
Adjusted PAT	1,853	1,976	2,231	2,859	3,632
Diluted EPS (Rs)	9.6	10.2	11.6	14.8	18.8
Diluted EPS growth (%)	21.5	6.6	12.9	28.1	27.0
DPS (Rs)	3.0	4.0	4.0	4.0	4.0
Dividend payout (%)	31.2	39.0	34.6	27.0	21.2
EBITDA margin (%)	30.0	30.7	28.8	31.2	33.0
EBIT margin (%)	27.2	26.2	23.9	26.3	28.7
Effective tax rate (%)	25.4	27.0	25.2	25.2	25.2
NOPLAT (pre-IndAS)	1,493	1,535	1,950	2,574	3,348
Shares outstanding (mn)	192.8	192.8	192.8	192.8	192.8

Source:	Company,	Emkay	Research

Cash flows					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
PBT	2,481	2,708	2,982	3,821	4,854
Others (non-cash items)	(432)	(400)	164	263	283
Taxes paid	(668)	(514)	(750)	(962)	(1,222)
Change in NWC	(447)	(862)	(671)	(653)	(729)
Operating cash flow	934	933	1,724	2,469	3,186
Capital expenditure	(1,031)	(923)	(2,100)	(2,393)	(1,969)
Acquisition of business	0	0	0	0	0
Interest & dividend income	0	0	0	0	0
Investing cash flow	(1,481)	166	(1,692)	(1,980)	(1,557)
Equity raised/(repaid)	0	0	0	0	0
Debt raised/(repaid)	0	(14)	0	0	0
Payment of lease liabilities	0	0	0	0	0
Interest paid	(6)	(30)	(33)	(33)	(33)
Dividend paid (incl tax)	(578)	(771)	(771)	(771)	(771)
Others	(168)	(33)	0	0	0
Financing cash flow	(752)	(849)	(804)	(804)	(804)
Net chg in Cash	(1,299)	250	(773)	(315)	825
OCF	934	933	1,724	2,469	3,186
Adj. OCF (w/o NWC chg.)	488	71	1,052	1,815	2,457
FCFF	(97)	10	(376)	76	1,217
FCFE	(154)	(23)	(409)	43	1,184
OCF/EBITDA (%)	42.3	37.8	54.8	60.5	62.0
FCFE/PAT (%)	(8.3)	(1.1)	(18.3)	1.5	32.6
FCFF/NOPLAT (%)	(6.5)	0.6	(19.3)	2.9	36.3

Source:	Company,	Emkay Research	1

Balance Sheet					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Share capital	193	193	193	193	193
Reserves & Surplus	13,228	14,498	15,959	18,047	20,908
Net worth	13,421	14,691	16,151	18,239	21,101
Minority interests	34	35	34	34	34
Deferred tax liability (net)	464	474	474	474	474
Total debt	7	54	54	54	38
Total liabilities & equity	13,926	15,254	16,714	18,802	21,646
Net tangible fixed assets	2,207	2,238	2,884	3,519	3,557
Net intangible assets	1,183	5,185	6,100	7,214	8,483
Net ROU assets	7	7	7	7	7
Capital WIP	0	0	0	0	0
Goodwill	0	0	0	0	0
Investments [JV/Associates]	21	21	21	21	21
Cash & equivalents	7,470	6,598	5,825	5,510	6,335
Current assets (ex-cash)	5,050	5,622	6,680	7,407	8,329
Current Liab. & Prov.	3,115	2,994	3,380	3,454	3,647
NWC (ex-cash)	1,935	2,629	3,300	3,953	4,683
Total assets	13,926	17,344	18,804	20,891	23,752
Net debt	(8,566)	(7,183)	(6,410)	(6,095)	(6,937)
Capital employed	13,926	15,254	16,714	18,802	21,646
Invested capital	5,331	10,085	12,318	14,721	16,757
BVPS (Rs)	69.6	76.2	83.8	94.6	109.4
Net Debt/Equity (x)	(0.6)	(0.5)	(0.4)	(0.3)	(0.3)
Net Debt/EBITDA (x)	(3.9)	(2.9)	(2.0)	(1.5)	(1.4)
Interest coverage (x)	0.0	0.0	0.0	0.0	0.0
RoCE (%)	17.9	18.8	18.9	21.7	24.2

Source: Company, Emkay Research

Valuations and key Ratios						
Y/E Mar	FY23	FY24	FY25E	FY26E	FY27E	
P/E (x)	54.7	51.3	45.4	35.4	27.9	
P/CE(x)	49.1	43.3	36.6	28.9	23.6	
P/B (x)	7.5	6.9	6.3	5.6	4.8	
EV/Sales (x)	12.6	11.7	8.7	7.3	6.1	
EV/EBITDA (x)	42.0	38.2	30.2	23.3	18.4	
EV/EBIT(x)	46.3	44.7	36.4	27.7	21.1	
EV/IC (x)	17.4	9.3	7.7	6.5	5.6	
FCFF yield (%)	(0.1)	0.0	(0.4)	0.1	1.3	
FCFE yield (%)	(0.2)	0.0	(0.4)	0.0	1.2	
Dividend yield (%)	0.6	0.8	0.8	0.8	0.8	
DuPont-RoE split						
Net profit margin (%)	25.2	24.6	20.4	21.8	23.3	
Total asset turnover (x)	0.5	0.6	0.7	0.7	0.8	
Assets/Equity (x)	1.0	1.0	1.0	1.0	1.0	
RoE (%)	13.6	14.1	14.5	16.6	18.5	
DuPont-RoIC						
NOPLAT margin (%)	20.3	19.1	17.9	19.6	21.5	
IC turnover (x)	1.6	1.0	1.0	1.0	1.0	
RoIC (%)	31.8	19.9	17.4	19.0	21.3	
Operating metrics						
Core NWC days	95.9	119.5	110.3	110.1	109.8	
Total NWC days	95.9	119.5	110.3	110.1	109.8	
Fixed asset turnover	2.1	1.3	1.2	1.1	1.1	
Opex-to-revenue (%)	39.5	40.4	37.3	36.5	36.0	

Source: Company, Emkay Research

## **RECOMMENDATION HISTORY - DETAILS**

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
05-Aug-24	492	580	Buy	Pulkit Chawla
26-May-24	478	550	Buy	Pulkit Chawla
25-Mar-24	365	465	Buy	Pulkit Chawla
11-Feb-24	358	465	Buy	Pulkit Chawla
09-Dec-23	371	465	Buy	Pulkit Chawla

Source: Company, Emkay Research

### **RECOMMENDATION HISTORY - TREND**



Source: Company, Bloomberg, Emkay Research

### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014, EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

#### RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

#### ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests 2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

#### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of August 24, 2024
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report 3 during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of August 24, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the 5. subject company at the end of the month immediately preceding the August 24, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

#### **Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

#### **Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

#### OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.